Literature DB >> 8554901

HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis.

D Campioni1, A Corallini, G Zauli, L Possati, G Altavilla, G Barbanti-Brodano.   

Abstract

Cells from BKV/tat transgenic mice were characterized for their tumorigenic phenotype in nude and syngeneic BDF mice. The results indicate that the BKV/tat recombinant transgene has a weak tumorigenic potential, mostly predisposing to oncogenesis, and that second events are required for the development of tumorigenicity. Tat is endogenously produced and released by tumor cells. It is taken up by recipient cells directly from the culture medium, without need of cell to cell contact. Extracellular Tat stimulates proliferation of cells from BKV/tat transgenic mice and protects them from apoptosis under conditions of serum starvation. Our results are in agreement with a model in which Tat induces its effects on target cells in two different ways. Growth promotion may require interaction of extracellular Tat with surface receptors eliciting a signal for cell proliferation, whereas intranuclear localization of Tat is necessary for transactivation of viral and cellular genes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554901     DOI: 10.1089/aid.1995.11.1039

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene.

Authors:  G Altavilla; A Caputo; M Lanfredi; C Piola; G Barbanti-Brodano; A Corallini
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Authors:  Francesco Carinci; Lorenzo Monasta; Corrado Rubini; Daniela Stramazzotti; Annalisa Palmieri; Elisabetta Melloni; Alex Knowles; Luca Ronfani; Giorgio Zauli; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-11-18       Impact factor: 3.850

Review 3.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

4.  Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1.

Authors:  F Macián; A Rao
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

5.  Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL.

Authors:  Arianna Gonelli; Oriano Radillo; Sara Drioli; Erika Rimondi; Paola Secchiero; Gian Maria Bonora
Journal:  Invest New Drugs       Date:  2010-12-02       Impact factor: 3.850

6.  The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Authors:  Giorgio Zauli; Claudio Celeghini; Elisabetta Melloni; Rebecca Voltan; Manuele Ongari; Mario Tiribelli; Maria Grazia di Iasio; Francesco Lanza; Paola Secchiero
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 7.  Non-AIDS-defining cancers among HIV-infected patients.

Authors:  James Cutrell; Roger Bedimo
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

8.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon.

Authors:  M R López-Huertas; S Callejas; D Abia; E Mateos; A Dopazo; J Alcamí; M Coiras
Journal:  Nucleic Acids Res       Date:  2010-02-05       Impact factor: 16.971

10.  Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.

Authors:  Erika Rimondi; Paola Secchiero; Elisabetta Melloni; Vittorio Grill; Giorgio Zauli
Journal:  Invest New Drugs       Date:  2012-11-16       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.